Chimerix reported Q3 2024 financial results and provided operational updates. The Phase 3 ACTION study of dordaviprone for H3 K27M-mutant diffuse glioma is on track, with first interim overall survival data expected in Q3 2025. The Independent Data Monitoring Committee recommended continuing the study as planned after a safety review.Chimerix is preparing to submit dordaviprone for provisional approval in Australia in the coming months. The company reported a net loss of $22.9 million for Q3 2024, compared to $24.0 million in Q3 2023. Research and development expenses increased to $19.6 million from $17.4 million year-over-year.As of September 30, 2024, Chimerix had $152.4 million in capital available to fund operations. The company also promoted Dr. Josh Allen to Chief Scientific Officer. Chimerix continues to advance its pipeline, including completing enrollment in a Phase 1 dose escalation study of ONC206.

Chimerix reported Q3 2024 financial results and provided operational updates. The Phase 3 ACTION study of dordaviprone for H3 K27M-mutant diffuse glioma is on track, with first interim overall survival data expected in Q3 2025. The Independent Data Monitoring Committee recommended continuing the study as planned after a safety review.Chimerix is preparing to submit dordaviprone for provisional approval in Australia in the coming months. The company reported a net loss of $22.9 million for Q3 2024, compared to $24.0 million in Q3 2023. Research and development expenses increased to $19.6 million from $17.4 million year-over-year.As of September 30, 2024, Chimerix had $152.4 million in capital available to fund operations. The company also promoted Dr. Josh Allen to Chief Scientific Officer. Chimerix continues to advance its pipeline, including completing enrollment in a Phase 1 dose escalation study of ONC206.